DOCSLIB.ORG

208564Orig1s000

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
208564Orig1s000 CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 208564Orig1s000 CLINICAL REVIEW(S) Clinical Review Theresa H. van der Vlugt, M.D., M.P.H. Resubmission NDA 208564 Imvexxy™ (estradiol vaginal inserts) 4 mcg and 10 mcg CLINICAL REVIEW Application Type Class 2 Resubmission Application Number(s) NDA 208564 Priority or Standard Standard Submit Date(s) November 29, 2017 Received Date(s) November 29, 2017 PDUFA Goal Date May 29, 2018 Division/Office Division of Bone, Reproductive, and Urologic Products/Office of Drug Evaluation III Reviewer Name(s) Theresa H. van der Vlugt, M.D., M.P.H. Review Completion Date May 15, 2018 Established/Proper Name Estradiol vaginal insert (Proposed) Trade Name Imvexxy™ Applicant TherapeuticsMD Dosage Form(s) Intravaginal inserts Applicant Proposed Dosing 4 mcg insert administer intravaginally daily for 2 weeks, then 4 Regimen(s) mcg insert administered intravaginally two times per week (approximately 3 to 4 days apart) 10 mcg insert administered intravaginally daily for 2 weeks, then 10 mcg insert administered intravaginally two times per week (approximately 3 to 4 days apart) Applicant Proposed Treatment of moderate to severe dyspareunia, a symptom of Indication(s)/Population(s) vulvar and vaginal atrophy, due to menopause Recommendation on Approval Regulatory Action Recommended Postmenopausal women Indication(s)/Population(s) (if applicable) CDER Clinical Review Template 1 Version date: September 6, 2017 for all NDAs and BLAs Reference ID: 42696514271237 Clinical Review Theresa H. van der Vlugt, M.D., M.P.H. Resubmission NDA 208564 Imvexxy™ (estradiol vaginal inserts) 4 mcg and 10 mcg Table of Contents Glossary ..........................................................................................................................................6 1. Executive Summary.................................................................................................................8 1.1. Product Introduction........................................................................................................8 1.2. Conclusions on the Substantial Evidence of Effectiveness...............................................8 1.3. Benefit-Risk Assessment ..................................................................................................9 1.4. Patient Experience Data.................................................................................................15 2. Therapeutic Context..............................................................................................................15 2.1. Analysis of Condition......................................................................................................15 2.2. Analysis of Current Treatment Options .........................................................................16 3. Regulatory Background .........................................................................................................17 3.1. U.S. Regulatory Actions and Marketing History.............................................................17 3.2. Summary of Presubmission/Submission Regulatory Activity ........................................18 3.3. Foreign Regulatory Actions and Marketing History .......................................................27 4. Significant Issues from Other Review Disciplines Pertinent to Clinical Conclusions on Efficacy and Safety ................................................................................................................27 4.1. Office of Scientific Investigations (OSI) ..........................................................................27 4.2. Product Quality ..............................................................................................................27 4.3. Clinical Microbiology......................................................................................................31 4.4. Nonclinical Pharmacology/Toxicology ...........................................................................32 4.5. Clinical Pharmacology ....................................................................................................32 4.6. Devices and Companion Diagnostic Issues ....................................................................36 4.7. Consumer Study Reviews...............................................................................................36 5. Sources of Clinical Data and Review Strategy .......................................................................37 5.1. Table of Clinical Studies .................................................................................................38 5.2. Review Strategy .............................................................................................................38 6. Review of Relevant Individual Trials Used to Support Efficacy .............................................38 6.1. TXV14-01........................................................................................................................38 6.1.1. Study Design ...........................................................................................................38 CDER Clinical Review Template 2 Version date: September 6, 2017 for all NDAs and BLAs Reference ID: 42696514271237 Clinical Review Theresa H. van der Vlugt, M.D., M.P.H. Resubmission NDA 208564 Imvexxy™ (estradiol vaginal inserts) 4 mcg and 10 mcg 6.1.2. Study Results ..........................................................................................................39 7. Integrated Review of Effectiveness.......................................................................................40 7.1. Assessment of Efficacy Across Trials..............................................................................40 7.2. Additional Efficacy Considerations.................................................................................40 7.2.1. Considerations on Benefit in the Postmarket Setting.............................................40 7.2.2. Other Relevant Benefits..........................................................................................40 7.3. Integrated Assessment of Effectiveness ........................................................................41 8. Review of Safety....................................................................................................................41 8.1. Safety Review Approach ................................................................................................41 8.2. Review of the Safety Database ......................................................................................42 8.2.1. Overall Exposure.....................................................................................................63 8.2.2 Relevant characteristics of the safety population: .................................................64 8.2.3 Adequacy of the safety database: ..........................................................................64 8.3. Adequacy of Applicant’s Clinical Safety Assessments....................................................65 8.4. Safety Results.................................................................................................................65 8.5. Analysis of Submission-Specific Safety Issues ................................................................66 8.5.1. General and Endometrial Safety.............................................................................66 8.6. Safety Analyses by Demographic Subgroups .................................................................69 8.7. Specific Safety Studies/Clinical Trials .............................................................................69 8.8. Additional Safety Explorations.......................................................................................69 8.9. Safety in the Postmarket Setting ...................................................................................70 8.10. Integrated Assessment of Safety................................................................................70 9. Advisory Committee Meeting and Other External Consultations .........................................73 10. Labeling Recommendations ..................................................................................................73 10.1. Prescription Drug Labeling .........................................................................................73 11. Risk Evaluation and Mitigation Strategies (REMS) ................................................................77 12. Postmarketing Requirements and Commitments.................................................................77 13. Appendices............................................................................................................................77 CDER Clinical Review Template 3 Version date: September 6, 2017 for all NDAs and BLAs Reference ID: 42696514271237 Clinical Review Theresa H. van der Vlugt, M.D., M.P.H. Resubmission NDA 208564 Imvexxy™ (estradiol vaginal inserts) 4 mcg and 10 mcg 13.1. References..................................................................................................................77 13.2. Financial Disclosure ....................................................................................................77 CDER Clinical Review Template 4 Version date: September 6, 2017 for all NDAs and BLAs Reference ID: 42696514271237 Clinical Review Theresa H. van der Vlugt, M.D., M.P.H. Resubmission NDA 208564 Imvexxy™ (estradiol vaginal inserts) 4 mcg and 10 mcg Table of Tables
Load more

Recommended publications
  • Postmenopausal Pharmacotherapy Newsletter
    POSTMENOPAUSAL PHARMACOTHERAPY September, 1999 As Canada's baby boomers age, more and more women will face the option of Hormone Replacement Therapy (HRT). The HIGHLIGHTS decision can be a difficult one given the conflicting pros and cons. M This RxFiles examines the role and use of HRT, as well as newer Long term HRT carries several major benefits but also risks SERMS and bisphosphonates in post-menopausal (PM) patients. which should be evaluated on an individual and ongoing basis MContinuous ERT is appropriate for women without a uterus HRT MWomen with a uterus should receive progestagen (at least 12 HRT is indicated for the treatment of PM symptoms such as days per month or continuous low-dose) as part of their HRT vasomotor disturbances and urogenital atrophy, and is considered MLow-dose ERT (CEE 0.3mg) + Ca++ appears to prevent PMO primary therapy for prevention and treatment of postmenopausal MBisphosphinates (e.g. alendronate, etidronate) and raloxifene are osteoporosis (PMO).1 Contraindications are reviewed in Table 2. alternatives to HRT in treating and preventing PMO Although HRT is contraindicated in women with active breast or M"Natural" HRT regimens can be compounded but data is lacking uterine cancer, note that a prior or positive family history of these does not necessarily preclude women from receiving HRT.1 Comparative Safety: Because of differences between products, some side effects may be alleviated by switching from one product Estrogen Replacement Therapy (ERT) 2 to another, particularly from equine to plant sources or from oral to Naturally secreted estrogens include: topical (see Table 3 - Side Effects & Their Management).
    [Show full text]
  • MENEST ® Brand of Esterified Estrogens Tablets, USP
    PRESCRIBING INFORMATION MENEST ® brand of esterified estrogens tablets, USP WARNINGS 1. ESTROGENS HAVE BEEN REPORTED TO INCREASE THE RISK OF ENDOMETRIAL CARCINOMA. Three independent case control studies have shown an increased risk of endometrial cancer in postmenopausal women exposed to exogenous estrogens for prolonged periods.1–3 This risk was independent of the other known risk factors for endometrial cancer. These studies are further supported by the finding that incidence rates of endometrial cancer have increased sharply since 1969 in eight different areas of the United States with population-based cancer reporting systems, an increase which may be related to the rapidly expanding use of estrogens during the last decade.4 The three case control studies reported that the risk of endometrial cancer in estrogen users was about 4.5 to 13.9 times greater than in nonusers. The risk appears to depend on both duration of treatment1 and on estrogen dose.3 In view of these findings, when estrogens are used for the treatment of menopausal symptoms, the lowest dose that will control symptoms should be utilized and medication should be discontinued as soon as possible. When prolonged treatment is medically indicated, the patient should be reassessed on at least a semiannual basis to determine the need for continued therapy. Although the evidence must be considered preliminary, one study sug- gests that cyclic administration of low doses of estrogen may carry less risk than continuous administration3; it therefore appears prudent to utilize such a regimen. Close clinical surveillance of all women taking estrogens is important. In all cases of undiagnosed persistent or recurring abnormal vaginal bleeding, adequate diagnostic measures should be undertaken to rule out malignancy.
    [Show full text]
  • Estrogen Agents, Oral-Transdermal
    GEORGIA MEDICAID FEE-FOR-SERVICE ESTROGEN AGENTS, ORAL - TRANSDERMAL PA SUMMARY Preferred Non-Preferred Oral Estrogens Estradiol generic n/a Menest (esterified estrogens) Premarin (estrogens, conjugated) Oral Estrogen/Progestin Combinations Angeliq (drospirenone/estradiol) Bijuva (estradiol/progesterone) Estradiol/norethindrone and all generics for Activella Norethindrone/ethinyl estradiol and all generics for Femhrt Low Dose 0.5/2.5 (norethindrone/ethinyl Femhrt Low Dose estradiol) Jinteli and all generics for Femhrt 1/5 (norethindrone/ethinyl estradiol) Prefest (estradiol/norgestimate) Premphase (conjugated estrogens/medroxyprogesterone) Prempro (conjugated estrogens/medroxyprogesterone) Topical Estrogens Alora (estradiol transdermal patch) Divigel (estradiol topical gel) Estradiol transdermal patch (generic Climara) Elestrin (estradiol topical gel) Evamist (estradiol topical spray solution) Estradiol transdermal patch (generic Vivelle-Dot) Menostar (estradiol transdermal patch) Minivelle (estradiol transdermal patch) Vivelle-Dot (estradiol transdermal patch) Topical Estrogens/Progestin Combination Climara Pro (estradiol/levonorgestrel transdermal patch) n/a Combipatch (estradiol/norethindrone transdermal patch) Oral Selective Estrogen Receptor Modulator (SERMs) Raloxifene generic Duavee (conjugated estrogens/bazedoxifene) Osphena (ospemifene) LENGTH OF AUTHORIZATION: 1 year PA CRITERIA: Bijuva ❖ Approvable for the treatment of moderate to severe vasomotor symptoms associated with menopause in women with an intact uterus who have experienced inadequate response, allergies, contraindications, drug-drug interactions or intolerable side effects to at least two preferred oral estrogen/progestin combination products. Revised 6/29/2020 Norethindrone/Ethinyl Estradiol and All Generics for Femhrt Low Dose ❖ Prescriber must submit a written letter of medical necessity stating the reasons at least two preferred oral estrogen/progestin combination products, one of which must be brand Femhrt Low Dose, are not appropriate for the member.
    [Show full text]
  • Eraas for Menopause Treatment: Welcome the ‘Designer Estrogens’
    REVIEW CME LEARNING OBJECTIVE: Readers will tailor hormone therapy to the needs of the patient CREDIT HEATHER D. HIRSCH, MD, MS, NCMP ELIM SHIH, MD, NCMP HOLLY L. THACKER, MD, NCMP Assistant Professor, Clinical Internal Medicine, Division Department of Obstetrics and Gynecology, Director of Center for Specialized Women’s Health, of General Internal Medicine, The Ohio State University, Women’s Health Institute, Cleveland Clinic Department of Obstetrics and Gynecology, Women’s Columbus, and Center for Women’s Health, Health Institute, Cleveland Clinic; Professor, Cleveland The Ohio State University Wexner Medical Center, Clinic Lerner College of Medicine of Case Western Upper Arlington, OH Reserve University, Cleveland, OH ERAAs for menopause treatment: Welcome the ‘designer estrogens’ ABSTRACT strogen receptor agonist-antagonists E(ERAAs), previously called selective es- Estrogen receptor agonist-antagonists (ERAAs) selec- trogen receptor modulators (SERMs), have tively inhibit or stimulate estrogen-like action in targeted extended the options for treating the vari- tissues. This review summarizes how ERAAs can be used ous conditions that menopausal women suffer in combination with an estrogen or alone to treat meno- from. These drugs act differently on estrogen pausal symptoms (vasomotor symptoms, genitourinary receptors in different tissues, stimulating re- syndrome of menopause), breast cancer or the risk of ceptors in some tissues but inhibiting them breast cancer, osteopenia, osteoporosis, and other female in others. This allows selective inhibition or midlife concerns. stimulation of estrogen-like action in various target tissues.1 KEY POINTS This article highlights the use of ERAAs Tamoxifen is approved to prevent and treat breast cancer. to treat menopausal vasomotor symptoms It may also have beneficial effects on bone and on car- (eg, hot flashes, night sweats), genitourinary diovascular risk factors, but these are not approved uses.
    [Show full text]
  • Why the Product Labeling for Low-Dose Vaginal Estrogen Should Be Changed
    Menopause: The Journal of The North American Menopause Society Vol. 21, No. 9, pp. 911/916 DOI: 10.1097/gme.0000000000000316 * 2014 by The North American Menopause Society EDITORIAL Why the product labeling for low-dose vaginal estrogen should be changed his commentary summarizes the activities of several of a highly effective local treatment of a common condition clinicians and researchers to encourage modifications with medical risks and adverse effects on quality of life. We Tto the labeling of low-dose vaginal estrogen. Motivated contend that the boxed warning for low-dose vaginal es- by concerns of practicing clinicians that the boxed warning on trogen products is unjustified based on several lines of rea- the labels and package inserts for these products overstate po- soning described below, including the following: (a) the tential risks and thus adversely affect patient care, leaders dramatic differences in blood hormone levels achieved by in the field are spearheading an effort to encourage consider- low-dose vaginal estrogen (eg, Vagifem tablets [estradiol ation of alternative labeling, as discussed below. The members 10 Kg], Estring [releasing estradiol 7.5 Kg/d], or comparable of the Working Group on Women’s Health and Well-Being in low-dose vaginal estrogen cream formulations) versus con- Menopause have affiliations with a number of medical socie- ventional systemic estrogen therapy; (b) absence of ran- ties, including The North American Menopause Society, the domized trial evidence or consistent observational evidence American College of Obstetricians and Gynecologists, the En- linking low-dose vaginal estrogen to cancer, cardiovascular docrine Society, the American Society for Reproductive Med- disease, dementia, or any of the other conditions highlighted icine, the International Society for the Study of Women’s in the boxed warning; and (c) absence of evidence that changes in Sexual Health, and other professional organizations.
    [Show full text]
  • Chronic Unopposed Vaginal Estrogen Therapy
    October, 1999. The Rx Files: Q&A Summary S. Downey BSP, L.D. Regier BSP, BA Chronic Unopposed Vaginal Estrogen Therapy The question of whether progestagen opposition is required in a patient on chronic vaginal estrogen is controversial. The literature is not clear on this matter and the SOGC conference on Menopause did not reach a consensus. Endometrial hyperplasia is directly related to the dose and duration of estrogen therapy. The PEPI study showed that 10 per cent of women taking unopposed estrogen (equivalent to 0.625 mg CEE) will develop complex or atypical endometrial hyperplasia within 1 year. With long-term HRT, it is now considered standard practice to add progestagen opposition to oral estrogen therapy in women with an intact uterus. The case is less clear for vaginal estrogen therapy. The makers of Premarinâ vaginal cream indicate their product is for short term management of urogenital symptoms and the monograph clearly states "precautions recommended with oral estrogen administration should also be observed with this route". In one recent study looking at "Serum and tissue hormone levels of vaginally and orally administered estradiol" (Am J Obstet Gynecol 1999;180:1480-3), serum levels were 10 times higher after vaginal vs. oral administration for exactly the same dose while endometrial concentrations were 70 times higher. This suggests that in some cases very little estrogen is required vaginally to produce significant serum levels and there may be preferential absorption into the endometrium. Hence equivalent vaginal doses may sometimes be much lower on a mg per mg basis compared to oral, largely because of bypassing the "first pass" effect.
    [Show full text]
  • Low-Dose Vaginal Estrogen Therapy
    where it works locally to improve the quality of the skin by normalizing its acidity and making it thicker and better lu- bricated. The advantage of using local therapy rather than systemic therapy (i.e. hormone tablets or patches, etc.) is that much lower doses of hormone can be used to achieve good effects in the vagina, while minimizing effects on Low-Dose Vaginal other organs such as the breast or uterus. Vaginal estrogen comes in several forms such as vaginal tablet, creams or gel Estrogen Therapy or in a ring pessary. Is local estrogen therapy safe for me? A Guide for Women Vaginal estrogen preparations act locally on the vaginal 1. Why should I use local estrogen? skin, and minimal, if any estrogen is absorbed into the bloodstream. They work in a similar way to hand or face 2. What is intravaginal estrogen therapy? cream. If you have had breast cancer and have persistent 3. Is local estrogen therapy safe for me? troublesome symptoms which aren’t improving with vagi- 4. Which preparation is best for me? nal moisturizers and lubricants, local estrogen treatment 5. If I am already on HRT, do I need local estrogen may be a possibility. Your Urogynecologist will coordinate the use of vaginal estrogen with your Oncologist. Studies so as well? far have not shown an increased risk of cancer recurrence in women using vaginal estrogen who are undergoing treat- ment of breast cancer or those with history of breast cancer. Which preparation is best for me? Your doctor will be able to advise you on this but most women tolerate all forms of topical estrogen.
    [Show full text]
  • Clinical Update on the Use of Ospemifene in the Treatment of Severe Symptomatic Vulvar and Vaginal Atrophy
    Journal name: International Journal of Women’s Health Article Designation: Review Year: 2016 Volume: 8 International Journal of Women’s Health Dovepress Running head verso: Palacios and Cancelo Running head recto: The use of ospemifene in the treatment of severe symptomatic VVA open access to scientific and medical research DOI: http://dx.doi.org/10.2147/IJWH.S110035 Open Access Full Text Article REVIEW Clinical update on the use of ospemifene in the treatment of severe symptomatic vulvar and vaginal atrophy Santiago Palacios1 Abstract: The physiological decrease in vaginal estrogens is accountable for the emergence of María Jesús Cancelo2 vulvar and vaginal atrophy (VVA) and its related symptoms such as vaginal dryness, dyspareunia, vaginal and/or vulvar irritation or itching, and dysuria. The repercussion of these symptoms 1Palacios Institute of Women’s Health, Madrid, Spain; 2Gynecology and on quality of life often makes it necessary to initiate treatment. Up until now, the treatments Obstetrics Department, Guadalajara available included vaginal moisturizers and lubricants, local estrogens, and hormonal therapy. University Hospital, University of Alcalá, Spain However, therapeutic options have now been increased with the approval of 60 mg ospemifene, the first nonhormonal oral treatment with an agonist effect on the vaginal epithelium and an endometrial and breast safety profile which makes it unique. This is the first selective estrogen receptor modulator indicated in women with moderate-to-severe vaginal atrophy not eligible For personal use only. for local estrogen treatment. Considering that “local estrogen noneligible women” are those in whom such treatment cannot be administered either because it is contraindicated or due to skill issues, who are averse to the mode and convenience of vaginal products’ administration or to their use on account of potential systemic absorption, or those who demonstrate dissatisfac- tion in terms of efficacy and safety, it is clear that there is a significant unmet medical need in VVA management.
    [Show full text]
  • Vaginal Sensitivity to Estrogen As Related to Mammary Tumor Incidence in Mice J.J
    Vaginal Sensitivity to Estrogen as Related to Mammary Tumor Incidence in Mice J.J. TRENTIN,PH.D.* (From the Department of Anatomy, Yale Unirersity School of Medicine, New Hauen, Connecticut) The demonstration of the importance of ovarian to estrogen bears no relation to the maternal ex- secretion or exogenous estrogen to a high mam trachromosomal factor. mary tumor incidence in mice was followed by Mühlbock(2,3), from the same laboratory, con numerous studies of the estrous cycles of mice of firmed the higher estrogen requirement (5-7 times different strains, in an attempt to correlate high as much) of the high tumor dba strain as compared mammary tumor incidence with some peculiarity to the low tumor C57 and 020 strains for a com of the cycle. In general, no significant and consist parable degree of vaginal stimulation by either in- ent correlation could be demonstrated in this travaginal or subcutaneous administration of regard. Korteweg and co-workers, however, fo estrogen. cused attention on the possibility that, whereas Sliimkin and Andervont (4) also reported on the outward manifestations of the cycle might be rela vaginal estrogen-sensitivity of three strains of mice tively constant, fundamental differences may exist of known mammary tumor incidence—the C57, in the sensitivity of the genital tissues to estrogen, C, and C3H strains. Again the high tumor strain and that such differences may be related to the was more resistant, the C3H strain requiring twice mammary tumor incidence. Van Gulik and Korte as much estrogen as the low tumor C57 and C, weg (5) reported that of one high tumor and two strains for a positive response in 50 per cent of the low tumor inbred strains, compared with regard to mice.
    [Show full text]
  • Management of Women with Premature Ovarian Insufficiency
    Management of women with premature ovarian insufficiency Guideline of the European Society of Human Reproduction and Embryology POI Guideline Development Group December 2015 1 Disclaimer The European Society of Human Reproduction and Embryology (hereinafter referred to as 'ESHRE') developed the current clinical practice guideline, to provide clinical recommendations to improve the quality of healthcare delivery within the European field of human reproduction and embryology. This guideline represents the views of ESHRE, which were achieved after careful consideration of the scientific evidence available at the time of preparation. In the absence of scientific evidence on certain aspects, a consensus between the relevant ESHRE stakeholders has been obtained. The aim of clinical practice guidelines is to aid healthcare professionals in everyday clinical decisions about appropriate and effective care of their patients. However, adherence to these clinical practice guidelines does not guarantee a successful or specific outcome, nor does it establish a standard of care. Clinical practice guidelines do not override the healthcare professional's clinical judgment in diagnosis and treatment of particular patients. Ultimately, healthcare professionals must make their own clinical decisions on a case-by-case basis, using their clinical judgment, knowledge, and expertise, and taking into account the condition, circumstances, and wishes of the individual patient, in consultation with that patient and/or the guardian or carer. ESHRE makes no warranty, express or implied, regarding the clinical practice guidelines and specifically excludes any warranties of merchantability and fitness for a particular use or purpose. ESHRE shall not be liable for direct, indirect, special, incidental, or consequential damages related to the use of the information contained herein.
    [Show full text]
  • Is Vaginal Estrogen Safe If I Had Cancer Or a Heart Attack?
    Is Vaginal Estrogen Safe If I had Cancer or a Heart Attack? 27th Annual Primary Health Care of Women Conference Samantha Kempner, MD Assistant Professor Department of Obstetrics and Gynecology Michigan Medicine Please consider the environment before printing this PowerPoint Learning Objectives Describe prevalence and impact of vaginal atrophy for menopausal women Review evidence-based approach to management of vaginal menopausal symptoms Discuss safety of vaginal estrogen for patients with cardiovascular disease or breast cancer Clinical Presentation 52yo G3P2012 calls office with 3rd complaint of dysuria in past 2 months. First time urine culture was obtained and showed E.Coli, second time no improvement on empiric antibiotics, third time culture negative. DDx: ?? Atrophy Sex Med. 2013 Dec: 1 (2): 44-53 D D X Please consider the environment before printing this PowerPoint Clin Med Insights Reprod Health. 2014 Jun 8;8:23-30. Sex Med. 2013 Dec: 1 (2): 44-53 Vulvovaginal Atrophy GSM (genitourinary syndrome of menopause) Impacts up to 85% of menopausal women Up to 70% of women do not discuss condition with a healthcare provider Symptoms include: • Vaginal or vulvar dryness • Dyspareunia • Discharge • Worsening Incontinence • Itching • UTIs Rx: Non-Hormonal Hormonal Other Medications Vaginal lubricants (use Local low-dose vaginal Prasterone (Vaginal DHEA) during intercourse) estrogen is the most • FDA approved vaginal Replens, Vagisil effective treatment for suppository Moisturizer, KY moderate to severe GSM: • MOA likely local Liquibeads
    [Show full text]
  • 36148 Federal Register / Vol
    36148 Federal Register / Vol. 85, No. 115 / Monday, June 15, 2020 / Rules and Regulations Sundstrand) model 54H60 propellers with a collection of information subject to the Administration (NARA). For information on blade having a serial number (S/N) below requirements of the Paperwork Reduction the availability of this material at NARA, S/N 813320. Act unless that collection of information email: [email protected], or go to: displays a currently valid OMB Control https://www.archives.gov/federal-register/cfr/ (d) Subject Number. The OMB Control Number for this ibr-locations.html. Joint Aircraft System Component (JASC) information collection is 2120–0056. Public Issued on June 3, 2020. Code 6111, Propeller Blade Section. reporting for this collection of information is estimated to be approximately 1 hour per Lance T. Gant, (e) Unsafe Condition response, including the time for reviewing Director, Compliance & Airworthiness This AD was prompted by the separation instructions, searching existing data sources, Division, Aircraft Certification Service. of a propeller blade that resulted in the loss gathering and maintaining the data needed, [FR Doc. 2020–12821 Filed 6–12–20; 8:45 am] of an airplane and 17 fatalities. The FAA is completing and reviewing the collection of BILLING CODE 4910–13–P issuing this AD to detect cracking in the information. All responses to this collection propeller blade taper bore. The unsafe of information are mandatory. Send condition, if not addressed, could result in comments regarding this burden estimate or failure of the propeller blade, blade any other aspect of this collection of DEPARTMENT OF JUSTICE separation, and loss of the airplane.
    [Show full text]